FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 334:400-402 February 8, 1996 Number 6 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Kobashigawa, J. A. Related Article by Shepherd, J. PubMed Citation

To the Editor: Kobashigawa and coworkers (Sept. 7 issue)¹ report that therapy with pravastatin beginning shortly after transplantation led to a reduction in the rates of hemodynamically important cardiac rejection and mortality and a lower incidence of coronary vasculopathy. Patients treated with pravastatin had total cholesterol and low-density lipoprotein (LDL) cholesterol levels that were 22 percent and 27 percent, respectively, lower than those in the control patients during the first year after transplantation. Natural-killer-cell cytotoxicity was also lower in the pravastatin group, and the authors speculate about the potential mechanisms whereby pravastatin may cause an increased state of immunosuppression. The . . . [Full Text of this Article]

References

This article has been cited by other articles:

• de Denus, S., Al-Jazairi, A., Loh, E., Jessup, M., Stanek, E. J, Spinler, S. A (2004). Dyslipidemias and HMG-CoA Reductase Inhibitor Prescription in Heart Transplant Recipients. The Annals of Pharmacotherapy 38: 1136-1141 [Abstract] [Full Text]